US FDA’s Rare Pediatric Disease Flexibility Rhetoric Undermined By Regenxbio’s CRL

 
• By Bridget Silverman
  
Rare disease drug developers face uncertain pathways to approval, especially in pediatrics. (Shutterstock)
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Rare Diseases

More from Pathways & Standards